FGFR2
FGFR2 is a receptor tyrosine kinase involved in cell growth and differentiation. Gene fusions and mutations are actionable in specific cancers, including cholangiocarcinoma.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where FGFR2 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Cholangiocarcinoma Solid Tumor · Bile Duct |
|
Approvals defined at the solid tumor level where FGFR2 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report FGFR2 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports FGFR2 as part of its biomarker panel.